A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors	Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Site, Skin and Connective Tissue Diseases, Thoracic Neoplasms, bile duct cancer, bile duct disorder, bile duct neoplasm, biliary tract disorder, breast cancer, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, esophageal cancer, esophageal disorder, gastric cancer, gastric neoplasm, intestinal disorder, lung disorder, lung neoplasm, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, non-small cell lung carcinoma, pancreas disorder, pancreatic neoplasm, rectal disorder, respiratory system disorder, respiratory tract neoplasm, skin disorder, stomach disorder	Recruiting	Phase 1	2023-09-21		NCT06043466

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Chongqing Precision Biotech Co., Ltd	34
Zhejiang University	194

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
The First Affiliated Hospital of Zhejiang University School of Medicine	Hangzhou	China	18
the Second Affiliated Hospital of Zhejiang University School of Medicine	Hangzhou	China	29